| Literature DB >> 35692679 |
Yusuke Kawai1, Mitsushige Sugimoto1, Mariko Hamada1, Eri Iwata1, Ryota Niikura1, Naoyoshi Nagata1, Masakatsu Fukuzawa2, Takao Itoi2, Takashi Kawai1.
Abstract
In oral endoscopy, linked color imaging (LCI) detects atrophic border and gastric mucosal diseases better than white light imaging (WLI), but its usefulness in transnasal endoscopy has not been fully investigated. Here, we retrospectively compared WLI and LCI using the L*a*b* color space in images from 57 patients aged ≥20 years who had undergone transnasal endoscopy as part of a health check-up from May 2016 to January 2017. We measured color differences at the atrophic/non-atrophic and fundic/pyloric mucosal borders. Gastritis severity scored using the Kyoto classification of gastritis was similar between the two techniques. However, in patients with current and with past Helicobacter pylori infection, color difference at the atrophic border was greater with LCI (21.58 ± 6.97 and 27.34 ± 10.32, respectively) than with WLI [14.42 ± 5.95 (p = 0.004) and 17.9 ± 8.48 (p<0.001)]; in those never infected with Helicobacter pylori, color difference at the fundic/pyloric mucosal border was greater with LCI than with WLI (p<0.001). Because of its enhancement of atrophic border detection, we recommend linked color imaging as the method of choice for transnasal endoscopy in health check-ups, particularly for identifying people at high risk of gastric cancer.Entities:
Keywords: Helicobacter pylori; Kyoto classification of gastritis; atrophic border; linked color imaging; transnasal endoscopy
Year: 2022 PMID: 35692679 PMCID: PMC9130059 DOI: 10.3164/jcbn.21-145
Source DB: PubMed Journal: J Clin Biochem Nutr ISSN: 0912-0009 Impact factor: 3.179
Fig. 1.Workflow for patient enrollment to evaluate the atrophic border by transnasal endoscopy using linked color imaging.
Patient characteristics
| All patients | |||||
|---|---|---|---|---|---|
| Currently infected | Previously infected | Never infected | |||
| Demographics | |||||
| Age, years (mean ± SD) | 64.6 ± 13.8 | 62.5 ± 13.9 | 71.6 ± 12.4 | 62.8 ± 12.3 | 0.035 |
| Sex [male, | 27 (51.9%) | 6 (46.2%) | 11 (21.2%) | 10 (47.6%) | 0.626 |
| Body mass index, kg/m2 (mean ± SD) | 22.9 ± 3.18 | 23.0 ± 2.57 | 23.7 ± 3.82 | 22.0 ± 2.69 | 0.113 |
| | 13 (25.0%) | 13 (100%) | 0 (0%) | 0 (0%) | <0.001 |
| Diseases | |||||
| Hypertension [ | 17 (32.7%) | 3 (23.1%) | 7 (38.9%) | 7 (33.3%) | 0.649 |
| Diabetes mellitus [ | 4 (7.7%) | 1 (7.7%) | 3 (16.7%) | 0 (0%) | 0.15 |
| Heart disease [ | 17 (32.7%) | 4 (30.8%) | 8 (44.4%) | 5 (23.8%) | 0.386 |
| Cancer [ | 5 (9.6%) | 1 (7.7%) | 3 (16.7%) | 1 (4.8%) | 0.437 |
Severity of endoscopic gastritis in patients with different Helicobacter pylori infection statuses
| All patients | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currently infected | Previously infected | Never infected | ||||||||||||||
| WLI | LCI | WLI | LCI | WLI | LCI | WLI | LCI | |||||||||
| Kimura–Takemoto classification | ||||||||||||||||
| Atrophy | C0 | 19 | 18 | 1 | 0 | 0 | 1 | 0 | 0 | 0.98 | 19 | 18 | 0.598 | |||
| C1 | 2 | 2 | 0 | 0 | 0 | 0 | 2 | 2 | ||||||||
| C2 | 8 | 9 | 2 | 2 | 6 | 6 | 0 | 1 | ||||||||
| C3 | 2 | 2 | 0 | 0 | 2 | 2 | 0 | 0 | ||||||||
| O1 | 7 | 7 | 4 | 4 | 3 | 3 | 0 | 0 | ||||||||
| O2 | 10 | 9 | 4 | 4 | 6 | 5 | 0 | 0 | ||||||||
| O3 | 4 | 5 | 3 | 3 | 1 | 2 | 0 | 0 | ||||||||
| Kyoto classification | ||||||||||||||||
| Atrophy | A0 | 21 | 20 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 21 | 20 | 1 | |||
| A1 | 10 | 11 | 2 | 2 | 8 | 8 | 0 | 1 | ||||||||
| A2 | 21 | 21 | 11 | 11 | 10 | 10 | 0 | 0 | ||||||||
| Intestinal metaplasia | IM0 | 36 | 34 | 0.796 | 5 | 4 | 0.856 | 10 | 9 | 0.881 | 21 | 21 | 1 | |||
| IM1 | 4 | 6 | 2 | 3 | 2 | 3 | 0 | 0 | ||||||||
| IM2 | 12 | 12 | 6 | 6 | 6 | 6 | 0 | 0 | ||||||||
| Enlarged folds | H0 | 48 | 48 | 1 | 9 | 9 | 1 | 18 | 18 | 1 | 21 | 21 | 1 | |||
| H1 | 4 | 4 | 4 | 4 | 0 | 0 | 0 | 0 | ||||||||
| Nodular gastritis | N0 | 51 | 51 | 1 | 12 | 12 | 1 | 18 | 18 | 1 | 21 | 21 | 1 | |||
| N1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||||
| Diffuse redness | DR0 | 40 | 38 | 0.86 | 4 | 3 | 0.881 | 15 | 14 | 0.674 | 21 | 21 | 1 | |||
| DR1 | 7 | 9 | 4 | 5 | 3 | 4 | 0 | 0 | ||||||||
| DR2 | 5 | 5 | 5 | 5 | 0 | 0 | 0 | 0 | ||||||||
| Xanthoma | Negative | 46 | 46 | 1 | 11 | 11 | 1 | 14 | 14 | 1 | 21 | 21 | 1 | |||
| Positive | 6 | 6 | 2 | 2 | 4 | 4 | 0 | 0 | ||||||||
LCI, linked color imaging; WLI, white light imaging.
Superiority of LCI vs WLI for evaluating endoscopic findings
| All patients | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currently infected | Previously infected | Never infected | |||||||||||||
| WLI | Equal | LCI | WLI | Equal | LCI | WLI | Equal | LCI | WLI | Equal | LCI | ||||
| Atrophy | 0 | 41 | 11 | 0 | 10 | 3 | 0 | 10 | 8 | 0 | 20 | 1 | |||
| Intestinal metaplasia | 0 | 44 | 8 | 0 | 12 | 1 | 0 | 17 | 1 | 0 | 21 | 0 | |||
| Enlarged folds | 0 | 52 | 0 | 0 | 13 | 0 | 0 | 18 | 0 | 0 | 21 | 0 | |||
| Nodular gastritis | 0 | 52 | 0 | 0 | 13 | 0 | 0 | 18 | 0 | 0 | 21 | 0 | |||
| Diffuse redness | 0 | 50 | 2 | 0 | 12 | 1 | 0 | 17 | 1 | 0 | 21 | 0 | |||
| Xanthoma | 0 | 52 | 0 | 0 | 13 | 0 | 0 | 18 | 0 | 0 | 21 | 0 | |||
LCI, linked color imaging; WLI, white light imaging.
Color differences between atrophic and non-atrophic mucosa and between fundic and pyloric mucosa
| Currently or previously infected | Currently infected | Previously infected | Never infected | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WLI | LCI | WLI | LCI | WLI | LCI | WLI | LCI | ||||||||
| Border between atrophic and non-atrophic mucosa | |||||||||||||||
| Color | 16.08 ± 7.82 | 25.03 ± 9.72 | <0.001 | 14.42 ± 5.95 | 21.58 ± 6.97 | 0.004 | 17.1 ± 8.48 | 27.34 ± 10.32 | <0.001 | — | — | — | |||
| Border between fundic and pyloric mucosa | |||||||||||||||
| Color | — | — | — | — | — | — | — | — | — | 14.04 ± 4.24 | 28.71 ± 5.92 | <0.001 | |||
LCI, linked color imaging; WLI, white light imaging.